agn 190299 has been researched along with bezafibrate in 2 studies
| Studies (agn 190299) | Trials (agn 190299) | Recent Studies (post-2010) (agn 190299) | Studies (bezafibrate) | Trials (bezafibrate) | Recent Studies (post-2010) (bezafibrate) |
|---|---|---|---|---|---|
| 6 | 0 | 4 | 1,335 | 267 | 324 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrara, SJ; Scanlan, TS | 1 |
| Aiello, F; Caroleo, MC; Carullo, G; Cione, E; Governa, P; Manetti, F | 1 |
1 review(s) available for agn 190299 and bezafibrate
| Article | Year |
|---|---|
FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
Topics: Binding Sites; Drug Development; Humans; Hypoglycemic Agents; Ligands; Receptors, G-Protein-Coupled | 2021 |
1 other study(ies) available for agn 190299 and bezafibrate
| Article | Year |
|---|---|
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
Topics: Amides; Amidohydrolases; Animals; Blood-Brain Barrier; Brain; Diffusion; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Prodrugs; Receptors, Cytoplasmic and Nuclear; Tissue Distribution | 2020 |